



Cancer Immunotherapy and the PD-1/PD-L1 Checkpoint Pathway

Guest Editors:

Dr. Simona Serrati

IRCCS Istituto Tumori Giovanni
Paolo II, Bari, Italy

Dr. Francesca Margheri

Department of Experimental and
Clinical Biomedical Sciences
“Mario Serio”, University of
Florence, 50134 Firenze, Italy

Deadline for manuscript
submissions:

15 September 2024

Message from the Guest Editors

Dear Colleagues,

In recent years, cancer immunotherapy has made great strides, and, thanks to the understanding of the mechanisms underlying immunity in cancer, numerous therapies have been developed for different tumors. The efficiency of an immune checkpoint blockade with monoclonal antibodies in cancer treatment is remarkable, and an example of this is the success of PD-1/PD-L1 inhibition blockage. The current challenge is to understand the mechanisms of resistance as well as identify new predictive–prognostic markers implicated in the PD-1/PD-L1 checkpoint pathway. The purpose of this Special Issue is to investigate the molecular mechanisms that regulate immunotherapy in terms of response and resistance in depth and to identify biological markers useful for the personalization of therapies.

Dr. Simona Serrati

Dr. Francesca Margheri

Guest Editors





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and
Molecular Medicine, Faculty of
Health and Medical Sciences,
University of Copenhagen,
Blegdamsvej 3C, DK-2200
Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer
Science, Virginia Commonwealth
University, Richmond, VA 23284,
USA

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)

Contact Us

Biomolecules Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomolecules
biomolecules@mdpi.com
[X@Biomol_MDPI](https://twitter.com/Biomol_MDPI)